| JOSTING, A., H. MULLER, P. BORCHMANN, JW. BAARS, B. METZNER, H. DOHNER, I. AURER, Lenka ŠMARDOVÁ, D. NIEDERWIESER, K. SCHÄFER-ECKART, N. SCHMITZ, A. SUREDA, J. GLOSSMAN, V. DIEHL, D. DE JONG, M.L. HANSMANN, J. RAEMAEKERS and A. ENGERT. Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma. Journal of clinical oncology. United States: American Society of Clinical Oncology, 2010, vol. 28, No 34, p. 5074-5080, 6 pp. ISSN 0732-183X. |
Other formats:
BibTeX
LaTeX
RIS
@article{906577,
author = {Josting, A. and Muller, H. and Borchmann, P. and Baars, JW. and Metzner, B. and Dohner, H. and Aurer, I. and Šmardová, Lenka and Niederwieser, D. and SchäferandEckart, K. and Schmitz, N. and Sureda, A. and Glossman, J. and Diehl, V. and De Jong, D. and Hansmann, M.L. and Raemaekers, J. and Engert, A.},
article_location = {United States},
article_number = {34},
keywords = {Hodgkin lymphoma},
language = {eng},
issn = {0732-183X},
journal = {Journal of clinical oncology},
title = {Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma.},
volume = {28},
year = {2010}
}
TY - JOUR
ID - 906577
AU - Josting, A. - Muller, H. - Borchmann, P. - Baars, JW. - Metzner, B. - Dohner, H. - Aurer, I. - Šmardová, Lenka - Niederwieser, D. - Schäfer-Eckart, K. - Schmitz, N. - Sureda, A. - Glossman, J. - Diehl, V. - De Jong, D. - Hansmann, M.L. - Raemaekers, J. - Engert, A.
PY - 2010
TI - Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma.
JF - Journal of clinical oncology
VL - 28
IS - 34
SP - 5074-5080
EP - 5074-5080
PB - American Society of Clinical Oncology
SN - 0732183X
KW - Hodgkin lymphoma
N2 - High-dose chemotherapy (HDCT) followed by autologous stem-cell transplantation (PBSCT) has become the standard treatment for patients (pts) with relapsed Hodgkin's lymphoma (HL). The intensity of treatment needed is unclear. This European intergroup study evaluated the impact of sequential high-dose chemotherapy (SHDCT) before myeloablative therapy. PATIENTS:Pts with histologically confirmed, relapsed HL were treated with two cycles of DHAP. In the standard arm (A), pts received myeloablative therapy with BEAM followed by PBSCT. Pts in the experimental arm (B) also received sequential cyclophosphamide, methotrexate and etoposide in high-doses before BEAM. RESULTS:Mortality was similar in both arms (20% and 18%). With a median observation time of 42 mo., there was no significant difference in terms of FFTF (P = .56) and OS (P = .82) between arms. CONCLUSION:Compared with conventional HDCT, additional SHDCT is associated with more adverse effects and does not improve the prognosis of pts with relapsed HL.
ER -
JOSTING, A., H. MULLER, P. BORCHMANN, JW. BAARS, B. METZNER, H. DOHNER, I. AURER, Lenka ŠMARDOVÁ, D. NIEDERWIESER, K. SCHÄFER-ECKART, N. SCHMITZ, A. SUREDA, J. GLOSSMAN, V. DIEHL, D. DE JONG, M.L. HANSMANN, J. RAEMAEKERS and A. ENGERT. Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma. \textit{Journal of clinical oncology}. United States: American Society of Clinical Oncology, 2010, vol.~28, No~34, p.~5074-5080, 6 pp. ISSN~0732-183X.
|
